Human papillomavirus infection in head and neck cancer: The role of the secretory leukocyte protease inhibitor
Markus Hoffmann(Christian-Albrechts-Universität zu Kiel), W. Martin Kast(University of Southern California), Christoph Röcken(University Hospital Schleswig-Holstein), Jochen Haag(Christian-Albrechts-Universität zu Kiel), LENA HEBEBRAND(Christian-Albrechts-Universität zu Kiel), Elgar Susanne Quabius(Christian-Albrechts-Universität zu Kiel), Tomas Kahn(Deutsche Bank (Germany)), Anna R. Giuliano(Moffitt Cancer Center), Tim Waterboer(German Cancer Research Center), Markus Schmitt(GATC Biotech (Germany)), Gordana Halec(Tufts Medical Center), Silke Tribius(Universität Hamburg), Jürgen Hedderich(University Hospital Schleswig-Holstein), Tibor Görögh
Cited by 45
Related Papers
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840
Prevalence of HPV Infection among Men: A Systematic Review of the Literature
|The Journal of Infectious Diseases|2006|618
Multiplex Human Papillomavirus Serology Based on In Situ–Purified Glutathione S-Transferase Fusion Proteins
|Clinical Chemistry|2005|588